Suppr超能文献

用于监测冠状动脉疾病的预后、疾病严重程度和治疗效果的生物标志物。

Biomarkers to monitor the prognosis, disease severity, and treatment efficacy in coronary artery disease.

机构信息

Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, USA.

出版信息

Expert Rev Cardiovasc Ther. 2023 Jul-Dec;21(10):675-692. doi: 10.1080/14779072.2023.2264779. Epub 2023 Oct 26.

Abstract

INTRODUCTION

Coronary Artery Disease (CAD) is a prevalent condition characterized by the presence of atherosclerotic plaques in the coronary arteries of the heart. The global burden of CAD has increased significantly over the years, resulting in millions of deaths annually and making it the leading health-care expenditure and cause of mortality in developed countries. The lack of cost-effective strategies for monitoring the prognosis of CAD warrants a pressing need for accurate and efficient markers to assess disease severity and progression for both reducing health-care costs and improving patient outcomes.

AREA COVERED

To effectively monitor CAD, prognostic biomarkers and imaging techniques play a vital role in risk-stratified patients during acute treatment and over time. However, with over 1,000 potential markers of interest, it is crucial to identify the key markers with substantial utility in monitoring CAD progression and evaluating therapeutic interventions. This review focuses on identifying and highlighting the most relevant markers for monitoring CAD prognosis and disease severity. We searched for relevant literature using PubMed and Google Scholar.

EXPERT OPINION

By utilizing the markers discussed, health-care providers can improve patient care, optimize treatment plans, and ultimately reduce health-care costs associated with CAD management.

摘要

简介

冠心病(CAD)是一种常见的疾病,其特征是心脏冠状动脉中存在动脉粥样硬化斑块。多年来,CAD 的全球负担显著增加,导致每年数百万人死亡,使其成为发达国家主要的医疗保健支出和死亡原因。缺乏经济有效的 CAD 预后监测策略,迫切需要准确和有效的标志物来评估疾病的严重程度和进展,以降低医疗保健成本并改善患者的预后。

涵盖领域

为了有效地监测 CAD,预后生物标志物和成像技术在急性治疗期间和随着时间的推移对风险分层患者具有重要作用。然而,有超过 1000 个潜在的感兴趣标志物,因此识别具有监测 CAD 进展和评估治疗干预的实质性效用的关键标志物至关重要。这篇综述侧重于确定和强调用于监测 CAD 预后和疾病严重程度的最相关标志物。我们使用 PubMed 和 Google Scholar 搜索了相关文献。

专家意见

通过利用讨论的标志物,医疗保健提供者可以改善患者的护理,优化治疗计划,并最终降低与 CAD 管理相关的医疗保健成本。

相似文献

1
Biomarkers to monitor the prognosis, disease severity, and treatment efficacy in coronary artery disease.
Expert Rev Cardiovasc Ther. 2023 Jul-Dec;21(10):675-692. doi: 10.1080/14779072.2023.2264779. Epub 2023 Oct 26.
4
Biomarkers and cardiovascular events in patients with stable coronary disease in the ISCHEMIA Trials.
Am Heart J. 2023 Dec;266:61-73. doi: 10.1016/j.ahj.2023.08.007. Epub 2023 Aug 19.
5
Plaque surface irregularity and calcification length within carotid plaque predict secondary events in patients with coronary artery disease.
Atherosclerosis. 2017 Jan;256:29-34. doi: 10.1016/j.atherosclerosis.2016.11.008. Epub 2016 Nov 9.

引用本文的文献

1
Modified Lipid Particle Recognition: A Link Between Atherosclerosis and Cancer?
Biology (Basel). 2025 Jun 11;14(6):675. doi: 10.3390/biology14060675.
3
CircBTBD7-420aa Encoded by hsa_circ_0000563 Regulates the Progression of Atherosclerosis and Construction of circBTBD7-420aa Engineered Exosomes.
JACC Basic Transl Sci. 2025 Feb;10(2):131-147. doi: 10.1016/j.jacbts.2024.09.003. Epub 2024 Nov 13.
4
Current and future role of biomarkers in the monitoring and prognosis of coronary artery disease.
Future Cardiol. 2025 May;21(6):331-333. doi: 10.1080/14796678.2025.2477947. Epub 2025 Mar 10.
7
The modified exhaust method is used in open-heart surgery for cardiopulmonary bypass in children with congenital heart disease.
Heliyon. 2024 Sep 5;10(17):e37483. doi: 10.1016/j.heliyon.2024.e37483. eCollection 2024 Sep 15.
8
Efficacy and safety of Shen Gui capsules for chronic heart failure: a systematic review and meta-analysis.
Front Pharmacol. 2024 Apr 10;15:1347828. doi: 10.3389/fphar.2024.1347828. eCollection 2024.

本文引用的文献

1
Evaluation of neopterin levels and kynurenine pathway in patients with acute coronary syndrome.
Acute Crit Care. 2023 Aug;38(3):325-332. doi: 10.4266/acc.2023.00024. Epub 2023 Aug 30.
3
Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis.
Eur Heart J. 2023 Jan 21;44(4):293-300. doi: 10.1093/eurheartj/ehac577.
4
Emerging biomarkers for the detection of cardiovascular diseases.
Egypt Heart J. 2022 Oct 20;74(1):77. doi: 10.1186/s43044-022-00317-2.
5
Circulatory soluble LOX-1 is a novel predictor for coronary artery disease patients.
Cardiovasc J Afr. 2023;34(2):104-108. doi: 10.5830/CVJA-2022-038. Epub 2022 Oct 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验